MA53045A1 - Nucléase p?Cas9 - Google Patents

Nucléase p?Cas9

Info

Publication number
MA53045A1
MA53045A1 MA53045A MA53045A MA53045A1 MA 53045 A1 MA53045 A1 MA 53045A1 MA 53045 A MA53045 A MA 53045A MA 53045 A MA53045 A MA 53045A MA 53045 A1 MA53045 A1 MA 53045A1
Authority
MA
Morocco
Prior art keywords
nuclease
nucleic acid
relates
acid encoding
cas9
Prior art date
Application number
MA53045A
Other languages
English (en)
Other versions
MA53045B1 (fr
Inventor
Aleksandr Vladimirovich Karabelskii
Roman Alekseevich Ivanov
Dmitry Valentinovich Morozov
Dmitriy Aleksandrovich Madera
Konstantin Viktorovich Severinov
Sergey Anatolevich Shmakov
Dmitrii Aleksandrovich Sutormin
Georgii Evgenevich Pobegalov
Aleksandra Andreevna Vasileva
Polina Anatolevna Selkova
Anatolii Nikolaevich Arseniev
Tatyana Igorevna Zyubko
Iana Vitalevna Fedorova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA53045A1 publication Critical patent/MA53045A1/fr
Publication of MA53045B1 publication Critical patent/MA53045B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Abstract

L'invention concerne le domaine de la biotechnologie, de la biologie moléculaire et de la médecine et notamment une enzyme de nucléase et l'utilisation de cette enzyme de nucléase. Plus particulièrement, l'invention concerne une enzyme de nucléase p?Cas9 l'invention concerne également un acide nucléique codant pour cette nucléase, un construct génétique, un vecteur d'expression, un vecteur d'administration qui comprennent cet acide nucléique, un liposome comprenant cette nucléase ou cet acide nucléique codant cette nucléase, un procédé de production de nucléase, des procédés d'administration et une cellule hôte qui comprend l'acide nucléique codant pour cette nucléase.
MA53045A 2018-09-14 2019-09-13 Nucléase p?Cas9 MA53045B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018132816A RU2706298C1 (ru) 2018-09-14 2018-09-14 НУКЛЕАЗА PaCas9
PCT/RU2019/050154 WO2020055293A1 (fr) 2018-09-14 2019-09-13 Nucléase pаcas9

Publications (2)

Publication Number Publication Date
MA53045A1 true MA53045A1 (fr) 2022-02-28
MA53045B1 MA53045B1 (fr) 2022-08-31

Family

ID=68580023

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53045A MA53045B1 (fr) 2018-09-14 2019-09-13 Nucléase p?Cas9

Country Status (20)

Country Link
US (1) US20220064612A1 (fr)
EP (1) EP3851522A4 (fr)
JP (1) JP2022500044A (fr)
KR (1) KR20210062040A (fr)
CN (1) CN113272425A (fr)
AR (1) AR116403A1 (fr)
AU (1) AU2019341014A1 (fr)
BR (1) BR112021004746A2 (fr)
CA (1) CA3113215A1 (fr)
CL (1) CL2021000610A1 (fr)
CO (1) CO2021003285A2 (fr)
EA (1) EA202190676A1 (fr)
MA (1) MA53045B1 (fr)
MX (1) MX2021002933A (fr)
PE (1) PE20211111A1 (fr)
PH (1) PH12021550563A1 (fr)
RU (1) RU2706298C1 (fr)
TW (1) TW202016130A (fr)
WO (1) WO2020055293A1 (fr)
ZA (1) ZA202101681B (fr)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1319120C (fr) 1985-04-01 1993-06-15 John Henry Kenten Lignee cellulaire myelomateuse transformee et expression d'un gene codant pour un polypeptide d'eucaryote a l'aide de cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
RU2650819C2 (ru) * 2012-05-07 2018-04-17 Сангамо Терапьютикс, Инк. Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов
CN104507503A (zh) * 2012-06-29 2015-04-08 康斯乔最高科学研究公司(Csic) 用于递送生物活性化合物的功能化脂质体
EP3350203A4 (fr) * 2015-09-17 2019-06-26 The Regents of The University of California Polypeptides cas9 variants comprenant des insertions internes
RU2634395C1 (ru) * 2015-12-01 2017-10-26 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) Генетическая конструкция на основе системы редактирования генома crispr/cas9, кодирующая нуклеазу cas9, специфически импортируемую в митохондрии клеток человека
CA3029132A1 (fr) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materiaux et procedes de traitement de troubles lies a la douleur
AU2018240515A1 (en) * 2017-03-24 2019-08-01 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof

Also Published As

Publication number Publication date
CN113272425A (zh) 2021-08-17
RU2706298C1 (ru) 2019-11-15
WO2020055293A1 (fr) 2020-03-19
EP3851522A1 (fr) 2021-07-21
AR116403A1 (es) 2021-05-05
KR20210062040A (ko) 2021-05-28
MA53045B1 (fr) 2022-08-31
MX2021002933A (es) 2021-06-15
US20220064612A1 (en) 2022-03-03
PE20211111A1 (es) 2021-06-21
TW202016130A (zh) 2020-05-01
JP2022500044A (ja) 2022-01-04
EP3851522A4 (fr) 2022-06-01
EA202190676A1 (ru) 2021-06-08
BR112021004746A2 (pt) 2021-06-08
CA3113215A1 (fr) 2020-03-19
CO2021003285A2 (es) 2021-06-10
AU2019341014A1 (en) 2021-05-13
ZA202101681B (en) 2022-06-29
PH12021550563A1 (en) 2022-02-14
CL2021000610A1 (es) 2021-09-24

Similar Documents

Publication Publication Date Title
Wang et al. Genome editing for cancer therapy: delivery of Cas9 protein/sgRNA plasmid via a gold nanocluster/lipid core–shell nanocarrier
Zuris et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
AU2018352221B2 (en) Peptides and nanoparticles for intracellular delivery of mRNA
EP4253551A3 (fr) Nouveaux systèmes et enzymes de ciblage d'adn et d'arn crispr
MA44479B1 (fr) Arn transrepliquant
MX2020009514A (es) Anticuerpos anti-claudina 18.2 (cldn18.2).
EA202090034A1 (ru) Способы модификации сплайсинга рнк
EA202090817A1 (ru) Триспецифические белки и способы их применения
MX2018016389A (es) Composiciones y metodos para suministro de arn mensajero.
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
JP2017534285A5 (fr)
ATE494370T1 (de) Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren
EP4249064A3 (fr) Nouvelle protéine de fusion spécifique à cd137 et pd-l1
ZA202202628B (en) Novel crispr dna targeting enzymes and systems
WO2020197436A1 (fr) Procédé de production d'une préparation d'une nucléase recombinante hautement purifiée
MX2022000183A (es) Lipidos cationicos y usos de estos.
MX2021001578A (es) Proteina asociada a crispr novedosa y uso de la misma.
CA3010573A1 (fr) Bacterie produisant un monophosphoryl lipide a et procede de production d'un monophosphoryl lipide a en utilisant la bacterie
Kawamura et al. Intracellular signal-responsive gene carrier for cell-specific gene expression
Han et al. High homology-directed repair using mitosis phase and nucleus localizing signal
MA53045A1 (fr) Nucléase p?Cas9
MX2023007319A (es) Vacunas de acido nucleico.
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
Kanwar et al. Ribonucleases and their applications
MX2022007430A (es) Algas recombinantes con alta productividad de lipidos.